Recent Updates
Recently added Catalysts
SNDX Positive Sentiment

Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

Thursday, May 9, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Syndax Pharmaceuticals announced its participation in the Bank of America Securities 2024 Health Care Conference, scheduled for May 16, 2024. Members of the management team will engage in a fireside chat, which will be accessible via a live webcast. The company is known for its innovative cancer therapies, including revumenib and axatilimab.
Price reaction · baseline $22.38 (2024-05-08 close) · hit after-hours · clean, no other SNDX news in the window
day 0 close · peak
-1.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Syndax is actively participating in a prominent healthcare conference.
  • The company showcases its innovative pipeline of cancer therapies.
  • Live webcast allows broader access to the event.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+133%
120-day peak, hindsight
Typical move
5.3%
average across 8 past catalysts
Cash runway
~54 mo
Low dilution risk
Lead asset
entinostat
Phase 1 · Epithelial Ovarian Cancer

Full Press Release Details

WALTHAM, Mass. , May 9, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX ), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of the Syndax management team will participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on Thursday, May 16, 2024 , at 8:00 a.m. PT / 11:00 a.m. ET .
A live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com , where a replay of the event will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective menin inhibitor, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit. For more information, please visit www.syndax.com or follow the Company on X (formerly Twitter) and LinkedIn .
Syndax Contact Sharon Klahre Syndax Pharmaceuticals, Inc. [email protected] Tel 781.684.9827
SNDX-G

Frequently Asked Questions

When is the Syndax fireside chat scheduled?

The fireside chat is scheduled for May 16, 2024, at 8:00 a.m. PT.

How can I access the Syndax conference webcast?

The live webcast can be accessed from the Investor section of Syndax's website.

What therapies is Syndax developing?

Syndax is developing innovative cancer therapies, including revumenib and axatilimab.

Where can I find more information about Syndax?

More information can be found on Syndax's official website and social media.

ShareAdd on Google
Tags: SNDX Viatris Investor Conferences Healthcare Syndax Pharmaceuticals cancer therapies Bank of America health care conference
Last updated: May 9, 2024

Biotech snapshot

Cash runway
$548M liquidity · $10M/mo burn
~54 mo
Low dilution risk
Lead asset
entinostatPhase 1
Epithelial Ovarian Cancer →

Catalyst track record

+133%
best trade around SNDX's most recent catalyst

Peak hindsight return over a 120-day window, across 8 tracked FDA/PDUFA catalysts for SNDX.

See every catalyst's timing & PoA →